Acute Pain-Pipeline Review, H2 2016

Acute Pain-Pipeline Review, H2 2016


  • Products Id :- GMDHC8346IDB
  • |
  • Pages: 194
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Acute Pain-Pipeline Review, H2 2016

Summary

Global Markets Direct's, Acute Pain-Pipeline Review, H2 2016', provides an overview of the Acute Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Pain and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Acute Pain

The report reviews pipeline therapeutics for Acute Pain by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Acute Pain therapeutics and enlists all their major and minor projects

The report assesses Acute Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Acute Pain

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Acute Pain

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Acute Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Acute Pain Overview 9

Therapeutics Development 10

Pipeline Products for Acute Pain-Overview 10

Pipeline Products for Acute Pain-Comparative Analysis 11

Acute Pain-Therapeutics under Development by Companies 12

Acute Pain-Therapeutics under Investigation by Universities/Institutes 16

Acute Pain-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Unknown Stage Products 20

Acute Pain-Products under Development by Companies 21

Acute Pain-Products under Investigation by Universities/Institutes 25

Acute Pain-Companies Involved in Therapeutics Development 26

AcelRx Pharmaceuticals, Inc. 26

Adynxx, Inc. 27

Amorsa Therapeutics Inc. 28

AnaBios Corporation 29

Anavex Life Sciences Corp. 30

AngioChem Inc. 31

Antibe Therapeutics, Inc. 32

AskAt Inc. 33

Cara Therapeutics, Inc. 34

Centrexion Therapeutics Corp 35

Charleston Laboratories, Inc. 36

ChironWells GmbH 37

Crescita Therapeutics Inc. 38

Cytogel Pharma, LLC 39

Dompe Farmaceutici S.p.A. 40

Grunenthal GmbH 41

Iroko Pharmaceuticals, LLC 42

KemPharm, Inc. 43

KPI Therapeutics, Inc. 44

Laboratorios Del Dr. Esteve S.A. 45

Mallinckrodt Plc 46

Nanomerics Ltd 47

Nanotherapeutics, Inc. 48

Orbis Biosciences Inc 49

Orexo AB 50

Orion Oyj 51

Pacira Pharmaceuticals, Inc. 52

Phosphagenics Limited 53

Recro Pharma, Inc. 54

Scilex Pharmaceuticals, Inc. 55

Shulov Innovative Science Ltd. 56

Syntrix Biosystems, Inc. 57

Thar Pharmaceuticals, Inc. 58

Trevena, Inc. 59

Yungjin Pharm. Co., Ltd. 60

Acute Pain-Therapeutics Assessment 61

Assessment by Monotherapy Products 61

Assessment by Combination Products 62

Assessment by Target 63

Assessment by Mechanism of Action 66

Assessment by Route of Administration 69

Assessment by Molecule Type 71

Drug Profiles 73

(acetaminophen + benzhydrocodone hydrochloride) IR-Drug Profile 73

(acetaminophen + hydrocodone bitartarate) ER-Drug Profile 79

(acetaminophen + tramadol hydrochloride) SR-Drug Profile 81

(buprenorphine hydrochloride + naloxone hydrochloride)-Drug Profile 82

(celecoxib + tramadol hydrochloride)-Drug Profile 83

AAT-076-Drug Profile 85

alfentanil hydrochloride-Drug Profile 86

AMS-410 FA-Drug Profile 87

ANAVEX-1037-Drug Profile 88

ANAVEX-1066-Drug Profile 89

ANAVEX-1067-Drug Profile 90

ANAVEX-1079-Drug Profile 91

ANAVEX-1519-Drug Profile 92

ANG-2002-Drug Profile 93

ARX-04-Drug Profile 94

ATB-352-Drug Profile 99

AYX-1-Drug Profile 100

BBI-11008-Drug Profile 102

celecoxib-Drug Profile 103

CL-108-Drug Profile 104

CR-4056-Drug Profile 106

Cyt-1010-Drug Profile 107

dexmedetomidine hydrochloride-Drug Profile 109

DF-2593A-Drug Profile 112

difelikefalin-Drug Profile 113

Drug for Acute Pain-Drug Profile 121

ECP-1014-Drug Profile 122

ET-1-Drug Profile 123

FY-101C-Drug Profile 124

FY-103B-Drug Profile 125

grapiprant-Drug Profile 126

HPI-201-Drug Profile 128

HS-731-Drug Profile 129

ibuprofen-Drug Profile 130

ibuprofen-Drug Profile 131

ibuprofen-Drug Profile 132

ketamine hydrochloride-Drug Profile 133

lidocaine hydrochloride-Drug Profile 135

meloxicam-Drug Profile 136

meloxicam-Drug Profile 139

meloxicam ER-Drug Profile 140

Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain-Drug Profile 141

MR-309-Drug Profile 142

NM-0127-Drug Profile 144

oliceridine-Drug Profile 145

Omnitram-Drug Profile 150

Peptides to Target TRPV1 for Pain and Itch-Drug Profile 151

prednisone-Drug Profile 152

Prostatic Acid Phosphatase-Drug Profile 153

RO-656570-Drug Profile 154

Small Molecule to Block Nav1.9 Channel for Pain-Drug Profile 155

Small Molecules to Block Nav 1.7 for Pain-Drug Profile 156

Small Molecules to Block Nav 1.8 for Pain-Drug Profile 157

Synthetic Peptides to Target Mu Opioid Receptor and Delta Opioid Receptor for Pain-Drug Profile 158

T-109-Drug Profile 159

tapentadol hydrochloride-Drug Profile 160

TRV-734-Drug Profile 162

U-2902-Drug Profile 164

VPX-595-Drug Profile 166

ZEP-3-Drug Profile 167

Acute Pain-Dormant Projects 169

Acute Pain-Discontinued Products 176

Acute Pain-Product Development Milestones 178

Featured News & Press Releases 178

Appendix 189

Methodology 189

Coverage 189

Secondary Research 189

Primary Research 189

Expert Panel Validation 189

Contact Us 189

Disclaimer 190

List of Tables

Number of Products under Development for Acute Pain, H2 2016 14

Number of Products under Development for Acute Pain-Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 17

Number of Products under Development by Companies, H2 2016 (Contd..1) 18

Number of Products under Development by Companies, H2 2016 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Comparative Analysis by Late Stage Development, H2 2016 21

Comparative Analysis by Clinical Stage Development, H2 2016 22

Comparative Analysis by Early Stage Development, H2 2016 23

Comparative Analysis by Unknown Stage Development, H2 2016 24

Products under Development by Companies, H2 2016 25

Products under Development by Companies, H2 2016 (Contd..1) 26

Products under Development by Companies, H2 2016 (Contd..2) 27

Products under Development by Companies, H2 2016 (Contd..3) 28

Products under Investigation by Universities/Institutes, H2 2016 29

Acute Pain-Pipeline by AcelRx Pharmaceuticals, Inc., H2 2016 30

Acute Pain-Pipeline by Adynxx, Inc., H2 2016 31

Acute Pain-Pipeline by Amorsa Therapeutics Inc., H2 2016 32

Acute Pain-Pipeline by AnaBios Corporation, H2 2016 33

Acute Pain-Pipeline by Anavex Life Sciences Corp., H2 2016 34

Acute Pain-Pipeline by AngioChem Inc., H2 2016 35

Acute Pain-Pipeline by Antibe Therapeutics, Inc., H2 2016 36

Acute Pain-Pipeline by AskAt Inc., H2 2016 37

Acute Pain-Pipeline by Cara Therapeutics, Inc., H2 2016 38

Acute Pain-Pipeline by Centrexion Therapeutics Corp, H2 2016 39

Acute Pain-Pipeline by Charleston Laboratories, Inc., H2 2016 40

Acute Pain-Pipeline by ChironWells GmbH, H2 2016 41

Acute Pain-Pipeline by Crescita Therapeutics Inc., H2 2016 42

Acute Pain-Pipeline by Cytogel Pharma, LLC, H2 2016 43

Acute Pain-Pipeline by Dompe Farmaceutici S.p.A., H2 2016 44

Acute Pain-Pipeline by Grunenthal GmbH, H2 2016 45

Acute Pain-Pipeline by Iroko Pharmaceuticals, LLC, H2 2016 46

Acute Pain-Pipeline by KemPharm, Inc., H2 2016 47

Acute Pain-Pipeline by KPI Therapeutics, Inc., H2 2016 48

Acute Pain-Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016 49

Acute Pain-Pipeline by Mallinckrodt Plc, H2 2016 50

Acute Pain-Pipeline by Nanomerics Ltd, H2 2016 51

Acute Pain-Pipeline by Nanotherapeutics, Inc., H2 2016 52

Acute Pain-Pipeline by Orbis Biosciences Inc, H2 2016 53

Acute Pain-Pipeline by Orexo AB, H2 2016 54

Acute Pain-Pipeline by Orion Oyj, H2 2016 55

Acute Pain-Pipeline by Pacira Pharmaceuticals, Inc., H2 2016 56

Acute Pain-Pipeline by Phosphagenics Limited, H2 2016 57

Acute Pain-Pipeline by Recro Pharma, Inc., H2 2016 58

Acute Pain-Pipeline by Scilex Pharmaceuticals, Inc., H2 2016 59

Acute Pain-Pipeline by Shulov Innovative Science Ltd., H2 2016 60

Acute Pain-Pipeline by Syntrix Biosystems, Inc., H2 2016 61

Acute Pain-Pipeline by Thar Pharmaceuticals, Inc., H2 2016 62

Acute Pain-Pipeline by Trevena, Inc., H2 2016 63

Acute Pain-Pipeline by Yungjin Pharm. Co., Ltd., H2 2016 64

Assessment by Monotherapy Products, H2 2016 65

Assessment by Combination Products, H2 2016 66

Number of Products by Stage and Target, H2 2016 68

Number of Products by Stage and Mechanism of Action, H2 2016 71

Number of Products by Stage and Route of Administration, H2 2016 74

Number of Products by Stage and Molecule Type, H2 2016 76

Acute Pain-Dormant Projects, H2 2016 173

Acute Pain-Dormant Projects (Contd..1), H2 2016 174

Acute Pain-Dormant Projects (Contd..2), H2 2016 175

Acute Pain-Dormant Projects (Contd..3), H2 2016 176

Acute Pain-Dormant Projects (Contd..4), H2 2016 177

Acute Pain-Dormant Projects (Contd..5), H2 2016 178

Acute Pain-Dormant Projects (Contd..6), H2 2016 179

Acute Pain-Discontinued Products, H2 2016 180

Acute Pain-Discontinued Products (Contd..1), H2 2016 181

List of Figures

Number of Products under Development for Acute Pain, H2 2016 14

Number of Products under Development for Acute Pain-Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Comparative Analysis by Late Stage Development, H2 2016 21

Comparative Analysis by Clinical Stage Development, H2 2016 22

Comparative Analysis by Early Stage Products, H2 2016 23

Assessment by Monotherapy Products, H2 2016 65

Assessment by Combination Products, H2 2016 66

Number of Products by Top 10 Targets, H2 2016 67

Number of Products by Stage and Top 10 Targets, H2 2016 67

Number of Products by Top 10 Mechanism of Actions, H2 2016 70

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 70

Number of Products by Top 10 Routes of Administration, H2 2016 73

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 73

Number of Products by Molecule Types, H2 2016 75

Number of Products by Stage and Molecule Types, H2 2016 75

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AcelRx Pharmaceuticals, Inc.

Adynxx, Inc.

Amorsa Therapeutics Inc.

AnaBios Corporation

Anavex Life Sciences Corp.

AngioChem Inc.

Antibe Therapeutics, Inc.

AskAt Inc.

Cara Therapeutics, Inc.

Centrexion Therapeutics Corp

Charleston Laboratories, Inc.

ChironWells GmbH

Crescita Therapeutics Inc.

Cytogel Pharma, LLC

Dompe Farmaceutici S.p.A.

Grunenthal GmbH

Iroko Pharmaceuticals, LLC

KemPharm, Inc.

KPI Therapeutics, Inc.

Laboratorios Del Dr. Esteve S.A.

Mallinckrodt Plc

Nanomerics Ltd

Nanotherapeutics, Inc.

Orbis Biosciences Inc

Orexo AB

Orion Oyj

Pacira Pharmaceuticals, Inc.

Phosphagenics Limited

Recro Pharma, Inc.

Scilex Pharmaceuticals, Inc.

Shulov Innovative Science Ltd.

Syntrix Biosystems, Inc.

Thar Pharmaceuticals, Inc.

Trevena, Inc.

Yungjin Pharm. Co., Ltd.

Acute Pain Therapeutic Products under Development, Key Players in Acute Pain Therapeutics, Acute Pain Pipeline Overview, Acute Pain Pipeline, Acute Pain Pipeline Assessment

select a license
Single User License
USD 2000 INR 145100
Site License
USD 4000 INR 290200
Corporate User License
USD 6000 INR 435300

NEWSLETTER BY CATEGORY




Testimonials

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com